Gotham Asset Management buys $80,945,872 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Gotham Asset Management scooped up 48,500 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,016,142 shares of Gilead Sciences which is valued at $80,945,872.Gilead Sciences makes up approximately 0.91% of Gotham Asset Management’s portfolio.

Other Hedge Funds, Including , Permit Capital boosted its stake in GILD in the latest quarter, The investment management firm added 5,900 additional shares and now holds a total of 33,700 shares of Gilead Sciences which is valued at $2,684,542. Gilead Sciences makes up approx 1.76% of Permit Capital’s portfolio. Seven Eight Capital sold out all of its stake in GILD during the most recent quarter. The investment firm sold 5,465 shares of GILD which is valued $435,342.Cetera Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 4,601 additional shares and now holds a total of 49,090 shares of Gilead Sciences which is valued at $3,910,509. Gilead Sciences makes up approx 0.29% of Cetera Advisors’s portfolio.Winch Advisory Services reduced its stake in GILD by selling 150 shares or 51.19% in the most recent quarter. The Hedge Fund company now holds 143 shares of GILD which is valued at $11,391. Gilead Sciences makes up approx 0.01% of Winch Advisory Services’s portfolio.Pax World Management reduced its stake in GILD by selling 34,749 shares or 27.2% in the most recent quarter. The Hedge Fund company now holds 93,009 shares of GILD which is valued at $7,400,726. Gilead Sciences makes up approx 0.42% of Pax World Management’s portfolio.

Gilead Sciences closed down -0.96 points or -1.22% at $77.42 with 1,24,03,880 shares getting traded on Thursday. Post opening the session at $78.43, the shares hit an intraday low of $76.94 and an intraday high of $78.455 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.